Scopus BioPharma Statistics
Share Statistics
Scopus BioPharma has 42.08M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 42.08M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 34.22M |
| Failed to Deliver (FTD) Shares | 63 |
| FTD / Avg. Volume | 0.51% |
Short Selling Information
The latest short interest is 23.77K, so 0.06% of the outstanding shares have been sold short.
| Short Interest | 23.77K |
| Short % of Shares Out | 0.06% |
| Short % of Float | 0.07% |
| Short Ratio (days to cover) | 0.22 |
Valuation Ratios
The PE ratio is -0.18 and the forward PE ratio is null.
| PE Ratio | -0.18 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -0.31 |
| P/FCF Ratio | -0.25 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Scopus BioPharma Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05, with a Debt / Equity ratio of 0.
| Current Ratio | 0.05 |
| Quick Ratio | 0.05 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 1.77% and return on capital (ROIC) is 164.39%.
| Return on Equity (ROE) | 1.77% |
| Return on Assets (ROA) | -29.6% |
| Return on Capital (ROIC) | 164.39% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -893.06K |
| Employee Count | 13 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -105.05K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 38.66, so Scopus BioPharma 's price volatility has been higher than the market average.
| Beta | 38.66 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0 |
| Relative Strength Index (RSI) | 47.79 |
| Average Volume (20 Days) | 12.45K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -11.71M |
| Net Income | -11.61M |
| EBITDA | -11.71M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.55 |
Balance Sheet
The company has 124.58K in cash and 0 in debt, giving a net cash position of 124.58K.
| Cash & Cash Equivalents | 124.58K |
| Total Debt | 0 |
| Net Cash | 124.58K |
| Retained Earnings | -53.06M |
| Total Assets | 497.55K |
| Working Capital | -10.51M |
Cash Flow
In the last 12 months, operating cash flow was -8.13M and capital expenditures -1.55K, giving a free cash flow of -8.13M.
| Operating Cash Flow | -8.13M |
| Capital Expenditures | -1.55K |
| Free Cash Flow | -8.13M |
| FCF Per Share | -0.39 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SCPS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | -64381.62% |
Analyst Forecast
Currently there are no analyst rating for SCPS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -250.87 |
| Piotroski F-Score | 1 |